PL2552920T3 - Nowe wybiórcze związki antagonistów receptora NK-3, farmaceutyczne kompozycje i sposoby do zastosowania w zaburzeniach pośredniczonych przez receptory NK-3 - Google Patents

Nowe wybiórcze związki antagonistów receptora NK-3, farmaceutyczne kompozycje i sposoby do zastosowania w zaburzeniach pośredniczonych przez receptory NK-3

Info

Publication number: PL2552920T3
Authority: PL; Poland
Prior art keywords: novel; methods; pharmaceutical composition; mediated disorders; antagonist compounds
Prior art date: 2010-04-02

Application number

PL11711922T

Other languages

English (en)

Inventor

Hamid Hoveyda

Marie-Odile Roy

Graeme Lovat Fraser

Guillaume Dutheuil

Original Assignee

Ogeda Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-02

Filing date

2011-04-04

Publication date

2017-08-31

2011-04-04 Application filed by Ogeda Sa filed Critical Ogeda Sa

2017-08-31 Publication of PL2552920T3 publication Critical patent/PL2552920T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Rheumatology (AREA)
Psychology (AREA)
Pregnancy & Childbirth (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Theoretical Computer Science (AREA)
Databases & Information Systems (AREA)

PL11711922T 2010-04-02 2011-04-04 Nowe wybiórcze związki antagonistów receptora NK-3, farmaceutyczne kompozycje i sposoby do zastosowania w zaburzeniach pośredniczonych przez receptory NK-3 PL2552920T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP10305343		2010-04-02
US37902810P	2010-09-01	2010-09-01
EP11711922.2A EP2552920B1 (en)	2010-04-02	2011-04-04	Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders

Publications (1)

Publication Number	Publication Date
PL2552920T3 true PL2552920T3 (pl)	2017-08-31

Family

ID=42314283

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11711922T PL2552920T3 (pl)	2010-04-02	2011-04-04	Nowe wybiórcze związki antagonistów receptora NK-3, farmaceutyczne kompozycje i sposoby do zastosowania w zaburzeniach pośredniczonych przez receptory NK-3

Country Status (21)

Country	Link
US (4)	US8871761B2 (pl)
EP (2)	EP3176171A1 (pl)
JP (1)	JP5822911B2 (pl)
KR (1)	KR101878888B1 (pl)
CN (1)	CN102906093B (pl)
AU (1)	AU2011234398B8 (pl)
BR (1)	BR112012025101B1 (pl)
CA (1)	CA2793313C (pl)
DK (1)	DK2552920T3 (pl)
EA (1)	EA023161B1 (pl)
ES (1)	ES2627688T3 (pl)
HR (1)	HRP20170712T1 (pl)
HU (1)	HUE032770T2 (pl)
LT (1)	LT2552920T (pl)
MX (1)	MX342161B (pl)
PL (1)	PL2552920T3 (pl)
PT (1)	PT2552920T (pl)
RS (1)	RS55997B1 (pl)
SI (1)	SI2552920T1 (pl)
SM (1)	SMT201700282T1 (pl)
WO (1)	WO2011121137A1 (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2695903B2 (ja)	1989-03-10	1998-01-14	沖電気工業株式会社	音声パケット欠落補償波形の歪量算出方式
WO2010125102A1 (en) *	2009-04-29	2010-11-04	Glaxo Group Limited	5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS
WO2011082010A1 (en) *	2009-12-29	2011-07-07	Eli Lilly And Company	Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia
US10065960B2 (en)	2010-04-02	2018-09-04	Ogeda Sa	NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
MX342161B (es)	2010-04-02	2016-09-19	Euroscreen Sa	Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
MX367774B (es)	2011-10-03	2019-09-04	Ogeda S A	N-ACIL-5,6,7, (8-SUSTITUIDO)-TETRAHIDRO- [1,2,4] TRIAZOLO [4,3-a] PIRAZINAS QUIRALES, NOVEDOSAS, COMO ANTAGONISTAS SELECTIVOS DE RECEPTOR DE NK-3; COMPOSICIÓN FARMACÉUTICA, MÉTODOS PARA USO EN TRASTORNOS MEDIADOS POR RECEPTOR DE NK-3 Y SU SÍNTESIS QUIRAL.
JP6294953B2 (ja)	2013-03-14	2018-03-14	ヤンセンファーマシューティカエヌ．ベー．	Ｐ２ｘ７調節物質
ES2689526T3 (es)	2013-03-14	2018-11-14	Janssen Pharmaceutica Nv	Moduladores de P2X7
TWI627174B (zh)	2013-03-14	2018-06-21	比利時商健生藥品公司	Ｐ２ｘ７調控劑
TWI599567B (zh)	2013-03-14	2017-09-21	健生藥品公司	Ｐ２ｘ７調節劑
WO2014154896A1 (en) *	2013-03-29	2014-10-02	Euroscreen Sa	NOVEL N-ACYL-(3-SUBSTITUTED)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
CA2907814C (en)	2013-03-29	2021-07-13	Euroscreen Sa	Novel n-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
US10183948B2 (en)	2013-03-29	2019-01-22	Ogeda Sa	N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
WO2014154895A1 (en) *	2013-03-29	2014-10-02	Euroscreen Sa	NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
AU2014255512A1 (en) *	2013-04-19	2015-11-12	Astrazeneca Ab	A NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
GB201315846D0 (en)	2013-09-05	2013-10-23	Imp Innovations Ltd	Method for treating or preventing hot flushes
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
DK3105226T3 (da)	2014-02-13	2019-10-14	Incyte Corp	Cyclopropylaminer som lsd1-inhibitorer
EP3105219B9 (en)	2014-02-13	2018-10-03	Incyte Corporation	Cyclopropylamines as lsd1 inhibitors
PT3105218T (pt)	2014-02-13	2019-12-05	Incyte Corp	Ciclopropilaminas como inibidores de lsd1
WO2016007722A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en)	2014-07-10	2016-04-16	Incyte Corp	Imidazopyrazines as LSD1 inhibitors
TWI687419B (zh)	2014-07-10	2020-03-11	美商英塞特公司	作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9758523B2 (en)	2014-07-10	2017-09-12	Incyte Corporation	Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016039983A1 (en) *	2014-09-12	2016-03-17	Janssen Pharmaceutica Nv	P2x7 modulating n-acyl-triazolopyrazines
EP3191492B1 (en)	2014-09-12	2019-01-09	Janssen Pharmaceutica NV	P2x7 modulators
CN107001289B (zh)	2014-09-25	2019-12-31	欧歌达有限公司	N-酰基-(3-取代的)-(8-取代的)-5,6-二氢-[1,2,4]三唑并[4,3-a]吡嗪的新手性合成
WO2016146712A1 (en)	2015-03-16	2016-09-22	Euroscreen Sa	Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
EP3626720A1 (en)	2015-04-03	2020-03-25	Incyte Corporation	Heterocyclic compounds as lsd1 inhibitors
KR102710120B1 (ko)	2015-08-12	2024-09-27	인사이트 홀딩스 코포레이션	Lsd1 저해제의 염
PE20190377A1 (es)	2016-04-22	2019-03-08	Incyte Corp	Formulaciones de un inhibidor de lsd 1
WO2017200857A1 (en) *	2016-05-18	2017-11-23	Merck Sharp & Dohme Corp.	Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders
JP2021014404A (ja) *	2017-10-13	2021-02-12	アステラス製薬株式会社	トリアゾロピラジン誘導体の塩及び結晶
IL276223B2 (en) *	2018-01-26	2024-03-01	Recordati Ind Chimica E Farmaceutica S P A	TRIAZOLE, IMIDAZOLE AND PYRROLE CONDENSED PIPERAZINE DERIVATIVES AND THEIR USE AS MODULATORS OF mGlu5 RECEPTORS
US10968200B2 (en)	2018-08-31	2021-04-06	Incyte Corporation	Salts of an LSD1 inhibitor and processes for preparing the same
CA3111309A1 (en)	2018-09-28	2020-04-02	Janssen Pharmaceutica Nv	Monoacylglycerol lipase modulators
CN113164459B (zh)	2018-09-28	2024-09-03	詹森药业有限公司	单酰基甘油脂肪酶调节剂
IL284159B2 (en)	2018-12-21	2024-08-01	Ogeda Sa	Synthesis of 3-methyl-4,2,1-thiadiazole-5-carboxyhydrazide or derivatives of its form deuterium methyl-d3
WO2020211798A1 (zh) *	2019-04-16	2020-10-22	上海翰森生物医药科技有限公司	含二并环类衍生物抑制剂、其制备方法和应用
CA3156100A1 (en)	2019-09-30	2021-04-08	Janssen Pharmaceutica Nv	Radiolabelled mgl pet ligands
CA3176946A1 (en)	2020-03-26	2021-09-30	Janssen Pharmaceutica Nv	Monoacylglycerol lipase modulators
CN113527307B (zh) *	2020-04-20	2024-10-11	上海翰森生物医药科技有限公司	含三唑基的并环类衍生物抑制剂、其制备方法和应用
CN113549074A (zh) *	2020-04-26	2021-10-26	上海翰森生物医药科技有限公司	含三唑基的并环类衍生物抑制剂、其制备方法和应用
EP4190784A4 (en)	2020-07-30	2025-01-15	Shanghai Hansoh Biomedical Co., Ltd.	NITROGEN-FUSED RING DERIVATIVE AS INHIBITOR, ITS PREPARATION METHOD AND ITS USE
EP4293023A4 (en) *	2021-04-21	2024-12-18	Changchun Genescience Pharmaceutical Co., Ltd.	Imidazole-containing condensed ring derivative, preparation method therefor, and application thereof in medicine
WO2024083150A1 (zh) *	2022-10-19	2024-04-25	长春金赛药业有限责任公司	一种nk3r拮抗剂的晶型及其制备方法和应用
JP2025534100A (ja) *	2022-10-21	2025-10-09	長春金賽薬業有限責任公司	インドリンスピロ環系化合物の結晶形、非晶質物質及び両者の製造方法と使用
WO2024083164A1 (zh) *	2022-10-21	2024-04-25	长春金赛药业有限责任公司	吲哚啉螺环类化合物的溶剂化物及其晶型、制备方法和应用
WO2024188143A1 (zh) *	2023-03-10	2024-09-19	山东绿叶制药有限公司	Nk-3受体拮抗剂化合物、药物组合物、其制备方法和应用
EP4628491A1 (en)	2024-04-05	2025-10-08	Química Sintética, S.A.	Synthesis of intermediates for the preparation of neurokinin-3 receptor antagonists

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1004609A (en)	1911-02-07	1911-10-03	Farbenfab Vorm Bayer F & Co	Triphenylmethane dye.
JP3252483B2 (ja)	1992-10-20	2002-02-04	東レ株式会社	３環性トリアゾロ誘導体の製造方法
EP1146873B1 (en)	1999-01-25	2005-03-16	Smithkline Beecham Corporation	Anti-androgens and methods for treating disease
CA2366858A1 (en)	1999-04-01	2000-10-12	Margaret Yuhua Chu-Moyer	Sorbitol dehydrogenase inhibitors
ATE373660T1 (de)	2002-03-25	2007-10-15	Merck & Co Inc	Heterocyclische beta-aminoverbindungen als inhibitoren der dipeptidylpeptidase zur behandlung bzw. prävention von diabetes
EP1537114B8 (en)	2002-08-07	2007-10-03	Novartis AG	Organic compounds as agents for the treatment of aldosterone mediated conditions
MY139563A (en)	2002-09-04	2009-10-30	Bristol Myers Squibb Co	Heterocyclic aromatic compounds useful as growth hormone secretagogues
AR043443A1 (es)	2003-03-07	2005-07-27	Merck & Co Inc	Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios
EP1670476A4 (en)	2003-09-30	2009-05-27	Merck & Co Inc	Phenylpyrrolidine-ETHER-tachykinin receptor Antagonist
BRPI0507495A (pt)	2004-02-18	2007-07-10	Astrazeneca Ab	composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
GB0509405D0 (en) *	2005-05-10	2005-06-15	Merck Sharp & Dohme	Therapeutic compounds
TWI378091B (en)	2006-03-09	2012-12-01	Eisai R&D Man Co Ltd	Multi-cyclic cinnamide derivatives
GB0610680D0 (en) *	2006-05-31	2006-07-12	Istituto Di Ricerche D Biolog	Therapeutic compounds
US7943617B2 (en) *	2006-11-27	2011-05-17	Bristol-Myers Squibb Company	Heterobicyclic compounds useful as kinase inhibitors
JP5485148B2 (ja) *	2007-06-21	2014-05-07	カラセラピューティクスインコーポレイテッド	置換イミダゾ複素環
WO2009050236A1 (de)	2007-10-19	2009-04-23	Boehringer Ingelheim International Gmbh	Neue piperazino-dihydrothienopyrimidin-derivate
PE20091093A1 (es)	2007-12-03	2009-08-25	Takeda Pharmaceutical	Compuesto heterociclico que contiene nitrogeno y su uso
EP2250155B1 (en)	2008-01-09	2013-07-03	Array Biopharma, Inc.	5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
EP2229394A1 (en)	2008-01-17	2010-09-22	Grünenthal GmbH	Substituted sulfonamide derivatives
EP2085398A1 (en) *	2008-02-01	2009-08-05	Merz Pharma GmbH & Co. KGaA	Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2090576A1 (en) *	2008-02-01	2009-08-19	Merz Pharma GmbH & Co.KGaA	6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
WO2010125102A1 (en)	2009-04-29	2010-11-04	Glaxo Group Limited	5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS
GB0907515D0 (en)	2009-04-30	2009-06-10	Glaxo Group Ltd	Compounds
WO2011007756A1 (ja)	2009-07-13	2011-01-20	武田薬品工業株式会社	複素環化合物及びその用途
US10065960B2 (en)	2010-04-02	2018-09-04	Ogeda Sa	NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
MX342161B (es)	2010-04-02	2016-09-19	Euroscreen Sa	Compuestos antagonistas selectivos de receptor nk-3 novedosos, composicion farmaceutica y metodos para utilizarse en trastornos transmitidos por receptores nk-3.
MX367774B (es)	2011-10-03	2019-09-04	Ogeda S A	N-ACIL-5,6,7, (8-SUSTITUIDO)-TETRAHIDRO- [1,2,4] TRIAZOLO [4,3-a] PIRAZINAS QUIRALES, NOVEDOSAS, COMO ANTAGONISTAS SELECTIVOS DE RECEPTOR DE NK-3; COMPOSICIÓN FARMACÉUTICA, MÉTODOS PARA USO EN TRASTORNOS MEDIADOS POR RECEPTOR DE NK-3 Y SU SÍNTESIS QUIRAL.
WO2014154896A1 (en)	2013-03-29	2014-10-02	Euroscreen Sa	NOVEL N-ACYL-(3-SUBSTITUTED)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
CA2907814C (en)	2013-03-29	2021-07-13	Euroscreen Sa	Novel n-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
WO2014154895A1 (en)	2013-03-29	2014-10-02	Euroscreen Sa	NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS

2011
- 2011-04-04 MX MX2012011132A patent/MX342161B/es active IP Right Grant
- 2011-04-04 CA CA2793313A patent/CA2793313C/en active Active
- 2011-04-04 ES ES11711922.2T patent/ES2627688T3/es active Active
- 2011-04-04 JP JP2013501872A patent/JP5822911B2/ja active Active
- 2011-04-04 HR HRP20170712TT patent/HRP20170712T1/hr unknown
- 2011-04-04 EP EP16205883.8A patent/EP3176171A1/en not_active Withdrawn
- 2011-04-04 PT PT117119222T patent/PT2552920T/pt unknown
- 2011-04-04 EA EA201290940A patent/EA023161B1/ru unknown
- 2011-04-04 CN CN201180017571.0A patent/CN102906093B/zh active Active
- 2011-04-04 KR KR1020127028933A patent/KR101878888B1/ko active Active
- 2011-04-04 SM SM20170282T patent/SMT201700282T1/it unknown
- 2011-04-04 DK DK11711922.2T patent/DK2552920T3/en active
- 2011-04-04 WO PCT/EP2011/055218 patent/WO2011121137A1/en not_active Ceased
- 2011-04-04 RS RS20170465A patent/RS55997B1/sr unknown
- 2011-04-04 SI SI201131183A patent/SI2552920T1/sl unknown
- 2011-04-04 BR BR112012025101-5A patent/BR112012025101B1/pt active IP Right Grant
- 2011-04-04 LT LTEP11711922.2T patent/LT2552920T/lt unknown
- 2011-04-04 EP EP11711922.2A patent/EP2552920B1/en active Active
- 2011-04-04 AU AU2011234398A patent/AU2011234398B8/en active Active
- 2011-04-04 PL PL11711922T patent/PL2552920T3/pl unknown
- 2011-04-04 HU HUE11711922A patent/HUE032770T2/en unknown
2012
- 2012-09-26 US US13/627,091 patent/US8871761B2/en active Active
2014
- 2014-08-29 US US14/473,147 patent/US9926325B2/en active Active
2018
- 2018-02-27 US US15/906,268 patent/US10544150B2/en active Active
2019
- 2019-12-20 US US16/722,353 patent/US20200125564A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2627688T3 (es)	2017-07-31
AU2011234398A2 (en)	2013-01-17
EA201290940A1 (ru)	2013-03-29
CA2793313C (en)	2018-01-23
US10544150B2 (en)	2020-01-28
CN102906093B (zh)	2016-01-13
MX2012011132A (es)	2013-03-08
EA023161B1 (ru)	2016-04-29
AU2011234398B8 (en)	2015-03-05
US20180194772A1 (en)	2018-07-12
US20140371218A1 (en)	2014-12-18
BR112012025101A2 (pt)	2017-06-20
EP3176171A1 (en)	2017-06-07
KR101878888B1 (ko)	2018-08-17
AU2011234398A1 (en)	2012-09-13
PT2552920T (pt)	2017-06-07
US8871761B2 (en)	2014-10-28
US20200125564A1 (en)	2020-04-23
WO2011121137A1 (en)	2011-10-06
JP5822911B2 (ja)	2015-11-25
MX342161B (es)	2016-09-19
CA2793313A1 (en)	2011-10-06
SMT201700282T1 (it)	2017-07-18
AU2011234398B2 (en)	2014-10-23
BR112012025101B1 (pt)	2021-08-31
CN102906093A (zh)	2013-01-30
EP2552920B1 (en)	2017-03-15
HRP20170712T1 (hr)	2017-07-28
LT2552920T (lt)	2017-06-12
EP2552920A1 (en)	2013-02-06
HUE032770T2 (en)	2017-10-30
JP2013523697A (ja)	2013-06-17
RS55997B1 (sr)	2017-09-29
KR20130021384A (ko)	2013-03-05
AU2011234398C1 (en)	2015-02-26
US9926325B2 (en)	2018-03-27
AU2011234398A8 (en)	2015-03-05
US20130023530A1 (en)	2013-01-24
DK2552920T3 (en)	2017-06-12
SI2552920T1 (sl)	2017-07-31

Publication	Publication Date	Title
PL2552920T3 (pl)	2017-08-31	Nowe wybiórcze związki antagonistów receptora NK-3, farmaceutyczne kompozycje i sposoby do zastosowania w zaburzeniach pośredniczonych przez receptory NK-3
HUS2300037I1 (hu)	2023-11-28	Piperidinon karboxamid azaindan CGRP receptor antagonisták
PL2259774T3 (pl)	2013-04-30	Sposoby i kompozycje dla wprowadzania antagonisty receptora interleukiny-1
IL225550A0 (en)	2013-06-27	4cxcr receptor antagonists
ZA201105323B (en)	2012-03-28	Agonists and antagonists of the sip5 receptor,and methods of uses thereof
PL2619212T3 (pl)	2016-09-30	Analogi buprenorfiny działające agonistycznie i/lub antagonistycznie na receptory opioidowe
IL221620A (en)	2017-04-30	Antagonist antibodies against the interleukin receptor 7 and methods for their use
SMT201600164B (it)	2016-07-01	Nuove n-acil-5, 6, 7, ( 8-s0stituito )-tetraidro-[1, 2, 4]triazolo[4, 3-a]pirazine chirali come antagonisti selettivi del recettore nk-3, composizione farmaceutica, e metodi per l'uso in disturbi mediati dal recettore nk-3
IL214572A (en)	2015-04-30	Annals of 9 - Alkylaryl - 9h - Furin - 6 - Converted Illamine, a Pharmaceutical Composition Containing Them and These Compounds That Are a Toll-like Colton Antagonist for the Treatment of Disease
IL218823A0 (en)	2012-06-28	Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
ZA201305576B (en)	2014-10-29	Trpm8 receptor antagonists
EP2617717A4 (en)	2014-01-01	ANTAGONIST OF P2X4 RECEIVER
IL241743A0 (en)	2015-11-30	Non-competitive nicotinic receptor antagonists
IL212170A (en)	2016-03-31	Mineral corticoid receptor antagonists, their atrophy isomers, their medicinal preparations and their use
EP2657225A4 (en)	2014-07-30	SUBSTITUTED METHYL AMINES, 5-HT6 SEROTONIN RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING
AU2011345414A1 (en)	2013-08-08	Substituted methyl amines, serotonin 5-HT6 receptor antagonists, methods for the production and use thereof
AP2803A (en)	2013-11-30	Pharmaceutical composition based on kinin B2 receptor antagonists and corticosteroids, and their use
ZA201105801B (en)	2012-04-25	Pharmaceutical composition containing leukotriene receptor antagonist and method for the preparation thereof